In the biotechnology and drugs complex, insiders are buying up a massive amount of stock in Halozyme Therapeutics (HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets. Insiders are loading up into strength here since this stock is up over 23% so far in 2012.
Halozyme Therapeutics has a market cap of $1.21 billion and an enterprise value of $1.15 billion. This stock trades at a rich valuation, with a price-to-sales of 21.17 and a price-to-book of 44.81. Its estimated growth rate for this year is 71.4%, and for next year it's pegged at -187.5%. This is a cash-rich company, since the total cash position on its balance sheet is $66.33 million and its total debt is zero.>>5 Biotech Stocks for 2012 A director and beneficial owner just bought 1.36 million shares, or $14.4 million worth of stock, at $10.61 per share. From a technical perspective, HALO is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong since it hit a recent low last October at $5.60 a share. Since tagging that low, shares of HALO have been making mostly higher lows and higher highs, which is bullish price action. This stock recently broke out above some near-term overhead resistance at $11.62 a share. If you're bullish on HALO, I would look for long biased trades as long as the stock is trending above that breakout price of $11.62. If this stock happens to pullback below the breakout price, then I would only get long near its 50-day moving average of $10.18 a share, as long as that moving average isn't violated to the downside. Follow @stockpickr
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV